Methylene blue retains in vitro activity against early ring-stage artemisinin-resistant Plasmodium falciparum (2026)

Peer-Reviewed Study · Verdier O; Christensen P; Kaewkanya C; Kobphan P; Beau C; Phyo AP; Imwong M; Chotivanich K; White NJ; Nosten F; Chaumeau V · May 5, 2026

Verdier O et al., 2026-05-05: Laboratory ring-survival study on clinical isolates from the Thai-Myanmar border showing methylene blue kills young rings of kelch13-mutant artemisinin-resistant parasites at 14-27 nM with no evidence of cross-resistance.

Methylene blue suppressed ring-stage survival at low nanomolar concentrations with no evidence of kelch13-mediated cross-resistance: the mean 50% inhibitory concentration (IC50) estimates were 23 nM (95% credible interval [CrI]: 15 to 37) for wild type, 27 nM (95% CrI: 21 to 36) for R561H and 14 nM (95% CrI: 10 to 20) for P441L.

Abstract

Verdier O et al., 2026-05-05: Laboratory ring-survival study on clinical isolates from the Thai-Myanmar border showing methylene blue kills young rings of kelch13-mutant artemisinin-resistant parasites at 14-27 nM with no evidence of cross-resistance. Study type: in vitro/ex vivo laboratory study on clinical isolates (modified ring survival assay); N=22 isolates (3 wild type, 9 R561H, 10 P441L); Thailand (Shoklo Malaria Research Unit). MB exposure 0-3 h post-invasion, nanomolar range; no human dosing. Funding: Wellcome Trust grant 220211 (PubMed record). Competing interests: none declared. Comparator: artemisinin-sensitive wild-type isolates. Published 2026 , latest item in this claim. Study type: lab.